• 1
    Fisher RL. Wasting in chronic gastrointestinal diseases. J Nutr. 1999; 129( 1S Suppl): 252S255S.
  • 2
    Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med. 2004; 116( Suppl 7A): 44S49S.
  • 3
    Gomollón F, Gisbert JP. Anemia and inflammatory bowel diseases. World J Gastroenterol. 2009; 15: 46594665.
  • 4
    Mijaè DD, Jankoviæ GL, Jorga J, et al. Nutritional status in patients with active inflammatory bowel disease: prevalence of malnutrition and methods for routine nutritional assessment. Eur J Intern Med. 2010; 21: 315319.
  • 5
    Geerling BJ, Badart-Smook A, Stockbrügger RW, et al. Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission. Am J Clin Nutr. 1998; 67: 919926.
  • 6
    Geerling BJ, Badart-Smook A, Stockbrügger RW, et al. Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls. Eur J Clin Nutr. 2000; 54: 514521.
  • 7
    Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006; 55: 426431.
  • 8
    Henriksen M, Jahnsen J, Lygren I, et al; IBSEN Study Group. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008; 57: 15181523.
  • 9
    Schreiber S, Howaldt S, Schnoor M, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med. 1996; 334: 619623.
  • 10
    Solem CA, Loftus EV Jr, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005; 11: 707712.
  • 11
    Karoui S, Ouerdiane S, Serghini M, et al. Correlation between levels of C-reactive protein and clinical activity in Crohn's disease. Dig Liver Dis. 2007; 39: 10061010.
  • 12
    Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2008; 6: 12181224.
  • 13
    Bergamaschi G, Di Sabatino A, Albertini R, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica. 2010; 95: 199205.
  • 14
    Louis E, Vernier-Massouille G, Grimaud JC, et al. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing cohort study [abstract 961]. Gastroenterology. 2009; 5( Suppl 1): A-146.
  • 15
    Ananthakrishnan AN, McGinley EL, Binion DG, et al. A novel risk score to stratify severity of Crohn's disease hospitalizations. Am J Gastroenterol. 2010; 105: 17991807.
  • 16
    Gasche C, Lomer MC, Cavill I, et al. Iron, anaemia, and inflammatory bowel diseases. Gut. 2004; 53: 11901197.
  • 17
    Wells CW, Lewis S, Barton JR, et al. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006; 12: 123130.
  • 18
    Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337: 10291035.
  • 19
    Hanauer SB, Feagan BG, Lichtenstein GR, et al; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 15411549.
  • 20
    Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC I trial. Gastroenterology. 2006; 130: 323333.
  • 21
    Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132: 5265.
  • 22
    Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007; 56: 12321239.
  • 23
    Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007; 146: 829838.
  • 24
    Ravel R. Clinical laboratory medicine: clinical application of laboratory data. 6th ed. St. Louis: Mosby; 1995.
  • 25
    Feldman D, Pike JW, Glorieux FH. Vitamin D. San Diego: Academic Press; 1997.
  • 26
    Foster R. Clinical laboratory investigation and psychiatry: a practical handbook. New York: Informa Healthcare; 2008.
  • 27
    Adams GA, Bresnick SD. On call surgery. 2nd ed. Philadelphia: Saunders/Elsevier; 2001.
  • 28
    World Health Organization. Worldwide prevalence of anaemia 1993–2005 [World Health Organization Web site]. Available at: Accessed June 21, 2011.
  • 29
    Fischbach FT, Dunning MB. A manual of laboratory and diagnostic tests. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
  • 30
    Marshall WJ, Bangert SK. Clinical biochemistry: metabolic and clinical aspects. 2nd ed. Philadelphia: Elsevier Health Sciences; 2008.
  • 31
    Colombel JF, Sandborn WJ, Rutgeerts P, et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol. 2009; 104: 11701179.
  • 32
    Payne RB, Carver ME, Morgan DB. Interpretation of serum total calcium: effects of adjustment for albumin concentration on frequency of abnormal values and on detection of change in the individual. J Clin Pathol. 1979; 32: 5660.
  • 33
    Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther. 2006; 24: 15071523.
  • 34
    Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357: 228238.
  • 35
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al; PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357: 239250.
  • 36
    Carlson CS, Aldred SF, Lee PK, et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet. 2005; 77: 6477.
  • 37
    Domènech E, Mañosa M, Masnou H, et al. Infliximab for the treatment of chronic anemia in Crohn's disease. Am J Gastroenterol. 2005; 100: 496.
    Direct Link:
  • 38
    Vijverman A, Piront P, Belaiche J, et al. Evolution of the prevalence and characteristics of anemia in inflammatory bowel diseases between 1993 and 2003. Acta Gastroenterol Belg. 2006; 69: 14.